Guide — Aerosol Therapy & Pharmacology
Inhaled Corticosteroids & Controllers
Controllers are the quiet half of inhaled therapy — they do nothing in the moment of an attack, but taken faithfully over time they are what keeps the airway calm. This guide covers inhaled corticosteroids, ICS/LABA combinations, and leukotriene modifiers: how they work, the rinse-and-spit that prevents thrush, and why they are never rescue drugs.
8 min read · Aerosol Therapy & Pharmacology
Written by Apex Respiratory Editorial Team
Educational use only. This material supports respiratory therapy education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional protocols, or physician orders. Always follow facility policies and current provider orders, and verify calculations independently before clinical use.
Overview
Inhaled corticosteroids — fluticasone, budesonide, beclomethasone, and mometasone — are anti-inflammatory controllers. They reduce airway inflammation and bronchial hyperresponsiveness over days to weeks, and they are the cornerstone of asthma maintenance therapy. Their effect is gradual and cumulative, not immediate.
The single most important point for the respiratory therapist and the patient is what an ICS is not: it is not a rescue medication. It does nothing for an acute bronchospasm in the moment. The controller and the reliever are different drugs with different jobs, and keeping that distinction clear is central to safe inhaled therapy.
Key Concepts
The controller toolkit runs from the first-line inhaled steroid out to oral adjuncts and biologic add-ons for severe disease.
| Controller class | Examples | Role |
|---|---|---|
| Inhaled corticosteroids | Fluticasone, budesonide, beclomethasone, mometasone | First-line anti-inflammatory controller; the cornerstone of asthma maintenance |
| ICS/LABA combinations | Budesonide/formoterol, fluticasone/salmeterol | Control plus sustained bronchodilation in one inhaler; ICS keeps the LABA off monotherapy |
| Leukotriene receptor antagonists | Montelukast | Oral adjunct controller added to inhaled therapy |
| Biologics | Anti-IgE, anti-IL-5 | Add-on agents for severe asthma |
- ICS/LABA combinations pair two jobs in one inhaler. Budesonide/formoterol and fluticasone/salmeterol deliver anti-inflammatory control plus sustained bronchodilation together, and the ICS component is what keeps the LABA off asthma monotherapy — a long-acting bronchodilator is never used alone in asthma.
- Leukotriene receptor antagonists are oral adjuncts. Montelukast is taken by mouth as an add-on controller to inhaled therapy, blocking the inflammatory effects of leukotrienes. Like an ICS, it works over time and is not a reliever.
- Biologics are reserved for severe asthma. Anti-IgE and anti-IL-5 agents are targeted add-ons layered on top of controller therapy when severe disease is not controlled by inhaled treatment alone.
- Adverse effects are mostly local. Oropharyngeal candidiasis (thrush), dysphonia or hoarseness, and a reflex cough are the common ICS effects. Systemic effects are minimal at usual doses; high doses can affect the adrenal axis, bone, and growth in children.
Assessment & Findings
- Improving control over time. Better symptom control and improved lung function over days to weeks is the bedside signal that the controller is working — the effect is a trend, not a single-dose change.
- Inspect the mouth for thrush. Look for white plaques of oropharyngeal candidiasis, a recognized local effect of inhaled steroid deposition.
- A hoarse voice. Dysphonia may signal local deposition in the larynx — a cue to reinforce rinse-and-spit and spacer technique.
- A reflex cough on dosing. A cough triggered by the inhaled agent is a common, generally benign local effect worth distinguishing from worsening disease.
RT Priorities / Interventions
- Teach that controllers work over time. Reinforce that an ICS must be taken on schedule even when the patient feels well, because the benefit comes from continuous anti-inflammatory effect — stopping it once symptoms ease lets the inflammation return.
- Teach rinse-and-spit after every dose. Have the patient rinse the mouth and spit after each inhaled corticosteroid to clear deposited drug and prevent thrush and dysphonia.
- Use a spacer. A spacer with a metered-dose inhaler cuts oropharyngeal deposition, reducing local side effects and improving the dose that reaches the airway.
- Separate the controller from the rescue inhaler. Make sure the patient can tell the daily controller apart from the reliever and knows which one to reach for when short of breath — confusing the two is dangerous.
Common Pitfalls
- Using an ICS as a rescue inhaler. An inhaled corticosteroid does nothing for an acute bronchospasm. Reaching for it during an attack instead of a short-acting bronchodilator is a dangerous mistake.
- Stopping it once the patient feels better. The controller is working precisely because it is being taken. Discontinuing it when symptoms settle lets the underlying inflammation flare again.
- Skipping the mouth rinse. Omitting rinse-and-spit leaves steroid in the mouth and throat and is the usual cause of preventable oral thrush and hoarseness.
- Confusing the controller with the reliever. Treating the two inhalers as interchangeable undermines maintenance control and leaves the patient under-treated in an emergency.
Board Exam Pearls
- An ICS is a controller, not a rescue drug — if a stem expects relief of an acute bronchospasm, the answer is a short-acting bronchodilator, not a steroid.
- Rinse and spit after every ICS dose to prevent thrush and dysphonia — a recurring patient-education answer.
- An inhaled corticosteroid is the first-line asthma controller and the cornerstone of maintenance therapy.
- Never a LABA alone — a long-acting bronchodilator in asthma must be paired with an ICS.
FAQ
Are inhaled corticosteroids a rescue or a controller medication?
Inhaled corticosteroids are controllers, not rescue medications. They are anti-inflammatory agents that reduce airway inflammation and hyperresponsiveness over days to weeks, and they must be taken on a schedule even when the patient feels well. They do nothing for an acute bronchospasm in the moment — that is the job of a short-acting bronchodilator. Using an ICS as a rescue inhaler is a serious error.
Why rinse your mouth after using an ICS?
Some of every inhaled corticosteroid dose deposits in the mouth and throat rather than the airway. Left there, that steroid promotes oropharyngeal candidiasis (thrush) and can cause a hoarse voice (dysphonia). Rinsing and spitting after each dose removes the deposited drug and prevents both. Using a spacer further reduces oropharyngeal deposition.
What is an ICS/LABA combination inhaler for?
An ICS/LABA combination — such as budesonide/formoterol or fluticasone/salmeterol — delivers an anti-inflammatory controller and a long-acting bronchodilator in a single inhaler. It pairs ongoing control with sustained bronchodilation for maintenance therapy, and importantly the ICS component keeps the LABA from ever being used as asthma monotherapy, which is associated with worse outcomes.
What are leukotriene receptor antagonists?
Leukotriene receptor antagonists, such as montelukast, are oral adjunct controllers. They block the inflammatory and bronchoconstrictive effects of leukotrienes and are taken by mouth as an add-on to inhaled controller therapy. Like an ICS, they work over time for maintenance control and are not rescue drugs.
Put it to work
Controller therapy is about how well-controlled the asthma really is. When a presentation makes you ask whether the airway is compensating, run the gas through the interpreter to read the acid–base picture behind the wheeze.
Open the ABG Interpreter →Related Resources
Sources
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (current annual report). GINA.
- Gardenhire DS. Rau's Respiratory Care Pharmacology. 10th ed. Elsevier; 2019.
- Kacmarek RM, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 12th ed. Elsevier; 2021.